The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study

References

• Mouliou DS, Pantazopoulos I, Gourgoulianis KI. COVID-19 smart diagnosis in the emergency department: all-in in practice. Expert Rev Respir Med. 2022;16(3):1–6.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Pantazopoulos I, Gourgoulianis KI. Social response to vaccine against COIVD-19: the underrated power of influence. JPM. 2021;12(1):15.
   Google Scholar
• Viana J, Van Dorp CH, Nunes A, et al. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun. 2021;12(1):3674.
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccination and prioritization strategies in the EU/EEA. Available online: https://www.ecdc.europa.eu/en/pubblications-data/COVID-19-vaccination and priorization strategies-eueea. (accessed on 8 July 2021).
   Google Scholar
• Harder T, Koch J, Vygen-Bonnet S. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV2 infection: interim results of a living systematic review. Euro Surveillance. 2021;26(28):2100563.
   Google Scholar
• Mouliou DS, Dardiotis E. Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: knowns and unknowns. Diagnostics. 2022;12(7):1555.
   Web of Science ®Google Scholar
• Vial T, Desctes J. Autoimmune diseases and vaccinations. Eur J Dermatol. 2004;14(2):86–90.
   PubMed Web of Science ®Google Scholar
• Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med. 2010;9(45):90–97.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-”vaccinosis”: a dangerous liaison? J Autoimmun. 2000;14(1):1–10.
   PubMed Web of Science ®Google Scholar
• Guimaraes LE, Baker B, Perricone C, et al. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.
   PubMed Web of Science ®Google Scholar
• Martirosyan A, Aminov R, Manukyan G. Environmental triggers od autoreactive responses: induction of antiphosholipid antibody formation. Front Immunol. 2019;10:1609.
   PubMed Web of Science ®Google Scholar
• Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev. 1993;14(1):107–120.
   PubMed Web of Science ®Google Scholar
• Wick G, Trieb K, Aguzzi A, et al. Possible role of human foamy virus in graves’ disease. Intevirology. 1993;35(1-4):101–107.
   PubMed Web of Science ®Google Scholar
• Jeffrey MG. Autoimmune encephalitis after herpes simplex encephalitis: insights into pathogenesis. Lancet Neurol. 2018;17(9):733–735.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162.
   PubMed Web of Science ®Google Scholar
• Yazdanpana N, Rezaei N. Autoimmune complication of COVID-19. J Med Virol. 2022;94(1):54–62.
   PubMed Web of Science ®Google Scholar
• Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661–1663. [17].
   PubMed Web of Science ®Google Scholar
• Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502–508.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med. 2020;382(17):e38.
   PubMed Web of Science ®Google Scholar
• Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898–907.
   PubMed Web of Science ®Google Scholar
• Li J, Liu HH, Yin XD, et al. COVID-19 illness and autoimmune diseases: recent insights. Inflamm Res. 2021;70(4):407–428.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Ruscitti P, et al. Could SarS-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524.
   PubMed Web of Science ®Google Scholar
• Aladawi M, Elfil M, Abu-Esheh B, et al. Guillain barre syndrome as a complication of COVID-19: a systematic review. Can J Neurol Sci. 2022;49(1):38–48.
   PubMed Web of Science ®Google Scholar
• Bonometti R, Sacchi MC, Stobbione P, et al. The first case of systemic lupus erythematous (SLE) trigger by COVID19 infection. Eur Rev Med Pharmacol Sci. 2020;24(18):9695–9697.
   PubMed Web of Science ®Google Scholar
• Vuille-Lessard E, Montani M, Bosch J, et al. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021;123:102710.
   PubMed Web of Science ®Google Scholar
• Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10(12):3592.
   PubMed Web of Science ®Google Scholar
• Liu Y, Shao Z, Wang H. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2022;209:75–79.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384(23):2254–2256.
   PubMed Web of Science ®Google Scholar
• Bril F, Al Diffalha S, Dean M, et al. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? J Hepatol. 2021;75(1):222–224.
   PubMed Web of Science ®Google Scholar
• Capecchi PL, Lazzerini PE, Brillanti S. Comment on "autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? J Hepatol. 2021;75(4):994–995.
   PubMed Web of Science ®Google Scholar
• Clayton-Chubb D, Schneider D, Freeman E, et al. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. J Hepatol. 2021;75(5):1249–1250.
   PubMed Web of Science ®Google Scholar
• Ghielmetti M, Schaufelberger HD, Mieli-Vergani G, et al. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity? J Autoimmun. 2021;123:102706.
   PubMed Web of Science ®Google Scholar
• Uchiyama Y, Fukasawa H, Ishino Y, et al. Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination. BMC Nephrol. 2022;23(1):216.
   PubMed Web of Science ®Google Scholar
• Abramson M, Mon-Wei Yu S, Campbell KN, et al. IgA nephropathy after SARS-CoV-2 vaccination. Kidney Med. 2021;3(5):860–863.
   PubMedGoogle Scholar
• Baimukhamedov C, Makhmudov S, Botabekova A. Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection. Int J Rheum Dis. 2021;24(11):1440–1441.
   PubMed Web of Science ®Google Scholar
• Sakai M, Takao K, Mizuno M, et al. Two cases of systemic lupus erythematosus (SLE) after administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Mod Rheumatol Case Rep. 2023;7(2):378–382.
   PubMedGoogle Scholar
• Hinterseher J, Hertl M, Didona D. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis. J Dtsch Dermatol Ges. 2023; Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386–401.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, WC, C4591001 Clinical Trial Group., et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–189.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, et al. COVID. 19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586(7830):594–599.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, mRNA-1273 Study Group., et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383(20):1920–1931.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, COVE Study Group., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA. Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
   PubMed Web of Science ®Google Scholar
• Chilamakuri B, S Agarwal S. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variant. Expert Rev Vaccines. 2022;21(1):47–67.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Marin M, et al. The advisory committeeon immunization pracrices’interim recommendation for use of moderna COVID-19 vaccine-United States. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653–1656.
   PubMed Web of Science ®Google Scholar
• Perumalswami P, Peng L, Odin JA. Vaccination as a triggering event for autoimmune hepatitis. Semin Liver Dis. 2009;29(3):331–334.
   PubMed Web of Science ®Google Scholar
• Vadala M, Poddighe D, Laurino C, et al. Vaccination and autoimmune diseases: prevention of adverse health effects on the horizon? Epma J. 2017;8(3):295–311.
   PubMed Web of Science ®Google Scholar
• Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Dardiotis E. Temelimab for MS and SARS-CoV-2: could it be a double-edged blessing? Mult Scler Relat Disord. 2022;64:103938.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Kotsiou OS, Gourgoulianis KI. Estimates of COVID-19 risk factors among social strata and predictors for a vulnerability to the infection. IJERPH. 2021;18(16):8701.
   Web of Science ®Google Scholar
• Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40(9):1601–1611.
   PubMedGoogle Scholar
• Mouliou DS, Gourgoulianis KI. False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives. Expert Rev Respir Med. 2021;15(8):993–1002.
   PubMed Web of Science ®Google Scholar
• Mouliou DS. Managing viral emerging infectious diseases via current molecular diagnostics in the emergency department: the tricky cases. Expert Rev anti Infect Ther. 2022;20(9):1163–1169.
   PubMed Web of Science ®Google Scholar
• Ryabkova VA, Churilov LP, Shoenfeld Y. Hyperstimulation of the immune system as a cause of autoimmune diseases. Annals RAMS. 2020;75(3):204–213.
   Google Scholar
• Hedrich CM. Shaping the spectrum-From autoinflammation to autoimmunity. Clin Immunol. 2016;165:21–28.
   PubMed Web of Science ®Google Scholar